Constella to acquire Lineberry Res Assoc

30 October 2006

North Carolina, USA-based Constella Group, a global provider of professional health services, has signed a definitive agreement to acquire Lineberry Research Associates (LRA), a full-service, US contract research organization and consulting firm based in Research Triangle Park, NC.

Founded in 1995, LRA is a provider of regulatory affairs, medical writing, product development strategy, clinical trial management and data management services for pharmaceutical and biotechnology companies. It employs more than 75 people, all of whom will join Constella's pharmaceutical product development business unit once the acquisition is complete, which is expected to occur within the next 30 days.

The combined organization will give Constella greater capacity and additional resources to expand its global platform to deliver full-service drug development programs, the company states.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight